排序方式: 共有2条查询结果,搜索用时 0 毫秒
1
1.
Ana-Alicia Beltran-Bless Brent Vandermeer Alexander Paterson Ian Gunstone Leonard Kaizer Angel Arnaout Lisa Vandermeer Mark Clemons 《The oncologist》2021,26(8):e1290-e1295
Although it is accepted that oncologists should plan for a future beyond full-time oncology, there is little practical guidance for a successful transition into retirement. Previously, we provided strategies for various aspects of retirement planning. However, this became significantly more complicated as we face newer issues such as the COVID-19 pandemic, the move to virtual patient care, greater awareness of burnout, and the increasing burden of regulatory issues such as the electronic medical record. It is evident that more prospective information is needed to guide oncologists in planning their retirement. 相似文献
2.
Ana-Alicia Beltran-Bless Lisa Vandermeer Mohammed F. K. Ibrahim Brian Hutton Risa Shorr Marie-France Savard Mark Clemons 《Current oncology (Toronto, Ont.)》2021,28(4):2523
Background: Non-compliance and non-persistence with endocrine therapy for breast cancer is common and usually related to treatment-induced side effects. There are anecdotal reports that simply changing the time of day when taking endocrine therapy (i.e., changing morning dosing to evening dosing or vice versa) can reduce side effects. Literature review: We conducted a literature review to evaluate whether changing the timing of tamoxifen and/or aromatase inhibitor administration impacted patient outcomes. No randomized control trials or prospective cohort studies that looked at time of day of endocrine therapy were identified through our review of literature from 1947 until August 2020. Conclusions: Given the rates of endocrine therapy non-compliance and non-persistence reported in the literature, ranging from 41–72% and 31–73%, respectively, simply changing the time of day when medications are taken could be an important strategy. We could identify no trials evaluating the effect of changes in timing of administration of endocrine therapy on breast cancer patient outcomes. Randomized control trials are clearly indicated for this simple and cost-effective intervention. 相似文献
1